Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ethambutol + isoniazid + N-acetyl cysteine + pyrazinamide + rifampicin
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This drug is a fixed-dose combination of five agents: ethambutol, isoniazid, N-acetyl cysteine, pyrazinamide, and rifampicin. Four of these—ethambutol, isoniazid, pyrazinamide, and rifampicin—are first-line antitubercular drugs used in the intensive phase of tuberculosis (TB) treatment. They act synergistically to inhibit various aspects of Mycobacterium tuberculosis metabolism and cell wall synthesis to prevent resistance and maximize bactericidal activity[2][3][4][8]. N-acetyl cysteine (NAC) is not a standard component in WHO-recommended TB regimens but may be included for its mucolytic properties or as an adjunctive antioxidant therapy; it acts by replenishing intracellular glutathione levels and reducing oxidative stress. The primary indication for this combination would be the treatment of active pulmonary or extrapulmonary tuberculosis.
- Other names
- RIPE + NACRIPE plus N-acetylcysteineRIPE+NAC (2m) and RI (4m)
02
Targets
rpoB (DNA-directed RNA polymerase subunit beta)InhAAftA (Arabinosyltransferase AftA)FASN (Fatty acid synthase)
Beyond the preview
Go deeper on ethambutol + isoniazid + N-acetyl cysteine + pyrazinamide + rifampicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ethambutol + isoniazid + N-acetyl cysteine + pyrazinamide + rifampicin.